B细胞特异性激活蛋白与CD20在淋巴组织增生性疾病中的表达  

Expression of B cell-specific activator protein and CD20 in lymphoproliferative disorders

作　　者：柳刚[1] 赵彤[1] 周新华[1] 朱梅刚[1] 

机构地区：[1]第一军医大学病理学教研室,广州510515

出　　处：《临床与实验病理学杂志》2003年第1期53-55,共3页Chinese Journal of Clinical and Experimental Pathology

基　　金：广东省社会发展攻关项目基金资助课题 (NoB3 0 10 1)

摘　　要：目的　探讨B细胞特异性激活蛋白 (Bcell specificactivatorprotein ,BSAP)在淋巴组织增生性疾病中表达情况及在淋巴瘤鉴别诊断中的意义。方法　观察 6 3例淋巴组织增生性疾病的组织病理学形态 ,按WHO新分类方案进行淋巴瘤分型 ,采用免疫组织化学S P法同步检测比较BSAP和CD2 0的表达。结果　 9例淋巴结反应性增生的B淋巴细胞 ,34例B细胞性淋巴瘤的瘤细胞均表达BSAP和CD2 0 ,但BSAP的中等到强阳性表达率 (6 9 8% )高于CD2 0 (5 3 5 % ) ,二者差异无显著性 (P >0 0 5 ) ;6例霍奇金淋巴瘤H/RS瘤细胞表达阳性率为 83 2 % ;14例T细胞淋巴瘤的肿瘤细胞均不表达BSAP。结论　BSAP表达定位于B淋巴细胞的核内 ,清晰易见 ,在B细胞性淋巴瘤表达多呈强阳性 ,可用于淋巴瘤的分型与鉴别诊断 。Purpose To investigate the expression of B cell specific activator protein (BSAP) in a group of lymphoproliferative disorders, and to elucidate the significance of it in differential diagnosis of lymphoma. Methods The histomorphology and immuophenotypes in 63 cases of lymphoproliferative disorder were examined and reclassified. Ultrasensitive S P immunohistochemical methods were employed to detect the BSAP and CD20. Results The B cells in 9 cases of lymph node reactive hyperplasia and tumor cells in 34 cases of B cell lymphoma all expressed BSAP and CD20,but BSAP's intensively positive rate (69 8%) was higher than that of CD20 (53 5%). There was no significant difference between the two intensively positive rates ( P >0 05). Five of 6 (83 2%) cases of Hodgkin's lymphoma(HL) were BSAP positive, and 14 cases of T cell lymphoma were negative. Conclusions BSAP is expressed in the nuclei of B lymphocytes and B cell lymphoma. It can be used in classification and differential diagnosis of lymphoma, and may be another important marker for B cell lymphoma.

关 键 词：B细胞特异性激活蛋白 BSAP CD20 淋巴组织增生性疾病 基因表达 免疫组织化学 淋巴瘤 肿瘤 

分 类 号：R733.4[医药卫生—肿瘤]